Shu Cheng

2.1k total citations · 1 hit paper
58 papers, 1.1k citations indexed

About

Shu Cheng is a scholar working on Pathology and Forensic Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Shu Cheng has authored 58 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 39 papers in Pathology and Forensic Medicine, 33 papers in Oncology and 18 papers in Molecular Biology. Recurrent topics in Shu Cheng's work include Lymphoma Diagnosis and Treatment (39 papers), CAR-T cell therapy research (17 papers) and Viral-associated cancers and disorders (16 papers). Shu Cheng is often cited by papers focused on Lymphoma Diagnosis and Treatment (39 papers), CAR-T cell therapy research (17 papers) and Viral-associated cancers and disorders (16 papers). Shu Cheng collaborates with scholars based in China, France and United Kingdom. Shu Cheng's co-authors include Pengpeng Xu, Weili Zhao, Li Wang, Li Wang, Di Fu, Jinyan Huang, Mengyuan Ji, Anne Janin, Yao‐Hui Huang and Weili Zhao and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Shu Cheng

55 papers receiving 1.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Butyrate-producing Eubacterium rectale suppresses lymphomagenesis by alleviating the TNF-induced TLR4/MyD88/NF-κB axis

2022 119 citations Xiaoqiang Xu, Di Fu et al. Cell Host & Microbe profile →

Peers

Countries citing papers authored by Shu Cheng

Since Specialization

Citations

This map shows the geographic impact of Shu Cheng's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shu Cheng with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shu Cheng more than expected).

Fields of papers citing papers by Shu Cheng

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Shu Cheng. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shu Cheng. The network helps show where Shu Cheng may publish in the future.

Co-authorship network of co-authors of Shu Cheng

This figure shows the co-authorship network connecting the top 25 collaborators of Shu Cheng. A scholar is included among the top collaborators of Shu Cheng based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Shu Cheng. Shu Cheng is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	A phase 2 study of zanubrutinib in combination with rituximab and lenalidomide in de novo diffuse large B-cell lymphoma 2025 ·Blood ·Pengpeng Xu, Yue Zhu, (unknown), Li Wang, Shu Cheng, Ying Qian, Yan Zhao, (unknown), Hongmei Yi, Binshen Ouyang, Xufeng Jiang, Biao Li, (unknown), (unknown), Weili Zhao	0
2	DDX3X mutation and Epstein-Barr virus cooperate to induce R-loop-dependent oncogenesis 2025 ·Cell Reports ·(unknown), Yuran Qiu, (unknown), Kun Cai, Shu Cheng, Huijuan Zhong, Di Fu, (unknown), Guoyu Meng, Yan Zhao, Zheng Ruan, Wenfang Wang, Min Lü, Jian Zhang, Chen Zhu, Saijuan Chen, Jie Xiong, Weili Zhao	0
3	Epigenetic regulation of Epstein–Barr virus: From bench to bedside 2024 ·SHILAP Revista de lepidopterología ·Xiao Gao, (unknown), Shu Cheng, (unknown), Jie Xiong, Weili Zhao	2
4	Cholesterol efflux from C1QB-expressing macrophages is associated with resistance to chimeric antigen receptor T cell therapy in primary refractory diffuse large B cell lymphoma 2024 ·Nature Communications ·Zi‐Xun Yan, (unknown), Q. L. Niu, (unknown), Wen Wu, Yue Zhu, Li Wang, Shu Cheng, (unknown), Zisong Zhou, Lingshuang Sheng, Weili Zhao	18
5	Targeted agents plus CHOP compared with CHOP as the first-line treatment for newly diagnosed patients with peripheral T-cell lymphoma (GUIDANCE-03): an open-label, multicentre phase 2 clinical trial 2024 ·The Lancet Regional Health - Western Pacific ·(unknown), Shu Cheng, Hongmei Jing, (unknown), Guohui Cui, Ting Niu, Jianzhen Shen, Huang Liang, Xin Wang, Yao‐Hui Huang, Li Wang, (unknown), Weili Zhao	4
6	Genomic and transcriptomic profiling of peripheral T cell lymphoma reveals distinct molecular and microenvironment subtypes 2024 ·Cell Reports Medicine ·Yao‐Hui Huang, Yuran Qiu, Qunling Zhang, (unknown), Hao Yu, Jianming Zhang, Lu Jiang, Mengmeng Ji, Pengpeng Xu, Li Wang, Shu Cheng, Weili Zhao	8
7	Positron emission tomography‐adapted therapy in low‐risk diffuse large B‐cell lymphoma: results of a randomized, phase III, non‐inferiority trial 2023 ·Cancer Communications ·Qing Shi, Yang He, Hongmei Yi, (unknown), Xufeng Jiang, Di Fu, Lei Dong, (unknown), Pengpeng Xu, Shu Cheng, Qi Song, Sai‐Juan Chen, Li Wang, Weili Zhao	4
8	Human endogenous retroviruses as epigenetic therapeutic targets in TP53-mutated diffuse large B-cell lymphoma 2023 ·Signal Transduction and Targeted Therapy ·Ying Fang, Mu‐Chen Zhang, Yang He, Chen Li, Hai Fang, Pengpeng Xu, Shu Cheng, Yan Zhao, Feng Yan, Qian Liu, Li Wang, Weili Zhao	18
9	Effects of gastrointestinal endoscopy at different time points on diagnosis and treatment of upper gastrointestinal bleeding in patients with liver cirrhosis. 2023 ·Videosurgery and Other Miniinvasive Techniques ·(unknown), (unknown), Shu Cheng, (unknown), Jun Xiao	1
10	Clinical and Molecular Features of Patients with Double/Triple Hit Large B-Cell Lymphoma 2023 ·Blood ·(unknown), Shu Cheng, Pengpeng Xu, Li Wang, Weili Zhao	1
11	Simplified algorithm for genetic subtyping in diffuse large B-cell lymphoma 2023 ·Signal Transduction and Targeted Therapy ·Rong Shen, Di Fu, Lei Dong, Mu‐Chen Zhang, Qing Shi, (unknown), Shu Cheng, Li Wang, Pengpeng Xu, Weili Zhao	46
12	Oncogenic Mutations and Tumor Microenvironment Alterations of Older Patients With Diffuse Large B-Cell Lymphoma 2022 ·Frontiers in Immunology ·Yue Zhu, Di Fu, Qing Shi, (unknown), Lei Dong, Hongmei Yi, Zhenhua Liu, Feng Yan, Qian Liu, Hai Fang, Shu Cheng, Li Wang, Qiang Tian, Pengpeng Xu, Weili Zhao	11
13	Butyrate-producing Eubacterium rectale suppresses lymphomagenesis by alleviating the TNF-induced TLR4/MyD88/NF-κB axis breakdown → 2022 ·Cell Host & Microbe ·(unknown), Xiaoqiang Xu, Di Fu, (unknown), Rong Fan, Hongmei Yi, Xiangyi He, Chaofu Wang, Binshen Ouyang, Ping Zhao, Li Wang, Pengpeng Xu, Shu Cheng, Zhifeng Wang, Duowu Zou, Lizhong Han, Weili Zhao	119
14	CircEAF2 counteracts Epstein-Barr virus-positive diffuse large B-cell lymphoma progression via miR-BART19-3p/APC/β-catenin axis 2021 ·Molecular Cancer ·(unknown), Zi‐Xun Yan, Jingjing Wen, Di Fu, Pengpeng Xu, Li Wang, Shu Cheng, Jianda Hu, Weili Zhao	24
15	SLC1A1 mediated glutamine addiction and contributed to natural killer T-cell lymphoma progression with immunotherapeutic potential 2021 ·EBioMedicine ·Jie Xiong, Nan Wang, Huijuan Zhong, Bowen Cui, Shu Cheng, Rui Sun, Jiayi Chen, Pengpeng Xu, Gang Cai, Li Wang, Xiao‐Jian Sun, Jinyan Huang, Weili Zhao	32
16	Clinical Efficacy and Tumor Microenvironment Influence in a Dose-Escalation Study of Anti-CD19 Chimeric Antigen Receptor T Cells in Refractory B-Cell Non-Hodgkin's Lymphoma 2019 ·Clinical Cancer Research ·(unknown), Li Li, Wen Wang, (unknown), Shu Cheng, Li Wang, Wen Wu, (unknown), Muharrem Müftüoğlu, Ming Hao, Su Yang, (unknown), Zhong Zheng, James Li, Weili Zhao	88
17	Clinical Response in Relapsed/Refractory (R/R) B-NHL Treated with the CD19-Directed CAR T-Cell Product JWCAR029 2019 ·Blood ·Zhitao Ying, Pengpeng Xu, Li Wang, Shu Cheng, Wen Wu, Wen Wang, Ming Hao, Su Yang, (unknown), James Li, Hongxia Zheng, Weili Zhao, Yuqin Song, Jun Zhu	7
18	Presence of multiple abnormal immunologic markers is an independent prognostic factor of diffuse large B-cell lymphoma 2019 ·Frontiers of Medicine ·Yiwen Cao, Zhenhua Liu, Wen Wu, Ying Qian, Qin Shi, Rong Shen, (unknown), Pengpeng Xu, Shu Cheng, Ye Jin, Yiming Lu, Chaofu Wang, Chengde Yang, Li Wang, Weili Zhao	1
19	Efficacy and Safety of JWCAR029 in Adult Patients with Relapsed and Refractory B-Cell Non-Hodgkin Lymphoma 2018 ·Blood ·Zi‐Xun Yan, Wen Wang, Zhong Zheng, Ming Hao, Su Yang, James Li, Shu Cheng, Li Wang, Weili Zhao	6
20	Localized primary gastrointestinal diffuse large B cell lymphoma received a surgical approach: an analysis of prognostic factors and comparison of staging systems in 101 patients from a single institution 2015 ·World Journal of Surgical Oncology ·(unknown), Li Wang, Yu Dong, Yang Shen, Shu Cheng, Li Zhang, Ying Qian, Zhixiang Shen, Qinyu Li, Weili Zhao	11

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact